StreetAlpha.app
Home › Stocks › GRCE

Grace Therapeutics, Inc. (GRCE)

$1.72
▼ −1.71%
LAST CLOSE · NOV 17

Grace Therapeutics develops reformulated medicines for rare diseases, led by an injectable form of nimodipine for patients with brain bleeding. It last closed at $1.72 on Nov 17, down 1.71% on the day. GRCE reports earnings on Mon, Feb 15, 2027.

AI Auto Pilots
Is GRCE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$21.4M
EPS (diluted)
−$1.16
Valuation
Market cap
$36.2M
21.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$21.3M
At Sep 30
Shareholder equity
$55.5M
Shares outstanding
21.0M
At Nov 11
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: −$9.8M−$9.8MFY2022FY2023: −$42.4M−$42.4MFY2023FY2024: −$12.9M−$12.9MFY2024FY2025: −$9.6M−$9.6MFY2025FY2026: −$7.8M−$7.8MFY2026

From GRCE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 15
2027 · Time not announced
Consensus EPS forecast
-$0.15
$2.3M revenue est.
Year-ago EPS
-$0.19
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

GRCE · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 8% below its 20 day and 16% below its 50 day average. It is 57% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $1.71, and the nearest resistance the Pivot R1 at $1.77.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.5%/day
Key levels
$5.1852 week high+201.2%
$2.71200 day average+57.6%
$2.12100 day average+23.3%
$1.9950 day average+15.7%
$1.93Swing high (Nov 9)+12.2%
$1.8520 day average+7.6%
$1.77Pivot R1+2.9%
$1.72Last close
$1.71Pivot−0.6%
$1.67Swing low (Oct 26)−2.9%
$1.66Pivot S1−3.5%
$1.6552 week low−4.1%
Indicators
RSI (14)35.31Weak, oversold below 30Neutral
MACD-0.06Below its signal lineBearish
Stochastic18.3Near the bottom of its rangeOversold
ADX (14)12.8No clear trend
Williams %R-81.5Oversold below −80, overbought above −20Oversold
CCI (20)-191.5Oversold below −100, overbought above 100Oversold
Rate of change−3.4%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GRCE

What happened before

See how GRCE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in GRCE in the last 90 days.

Loading…

See today’s whale options flow across the market →

GRCE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●17 buying vs 19 selling
  • ▲Held by funds +17.3 pts
  • ▲Funds holding +5
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3833+15.2%
In funds' top 1000–
Held by funds36.1%18.8%+17.3 pts
New / increased12 / 510 / 13−26.1%
Reduced / sold out11 / 83 / 11+35.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GRCE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRCE is in one of them and how their past GRCE trades turned out.

GRCE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GRCE in an article yet. Here's the latest on the wider market.

About Grace Therapeutics

Grace Therapeutics is a pharmaceutical company based in Princeton, New Jersey, that develops reformulated versions of existing medicines for rare and orphan diseases. Its lead candidate, GTx-104, is an injectable form of nimodipine designed for intravenous delivery to patients with aneurysmal subarachnoid hemorrhage, a type of stroke. Its target customers include hospitals, physicians and patients. Its product candidates are still in development and have not yet been approved for sale.

Headquarters
Princeton, NJ